SLC5A2 and type 1 diabetes mellitus: Similar effects on plasma glucagon secretion and glucose infusion rates were observed with the SGLT2 inhibitor dapagliflozin.<h4>Interpretation</h4>Enhanced K<sub>ATP</sub> channel activity in alpha-cells and/or increased paracrine inhibition by somatostatin impairs the counterregulatory glucagon response in T1D.